Health Leads

Belkins
For more than 20 years, we’ve been focused on addressing social determinants of health or as we like to call them, essential needs. We’re thrilled to that we no longer have to convince the healthcare system that factors like food, heat and housing are key to good health and are honored to be working alongside so many amazing organizations who are integrating essential needs interventions into care.

Related News

INNOVATION PHARMACEUTICALS GRANTS INTELLECTUAL PROPERTY AND COMMERCIALIZATION RIGHTS TO FOX CHASE CHEMICAL DIVERSITY FOR ANTIFUNGAL TECHNOLOGY

Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020

news image

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...

Read More

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

BioSpace: Biotech, | April 01, 2020

news image

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More

BUSINESS INSIGHTS

TREATMENT TO EXPAND GLOBAL LIBRARY OF MEDICINE WITH DERMATOLOGIC DISEASES

Treatment.com International Inc. | January 05, 2022

news image

Treatment.com International Inc. a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these diagnoses will bring another level of accuracy and specificity to the GLM, enhancing soon-to-be-released products such as the Treatment Mobile app, which is set for release this month.
Read More

BUSINESS INSIGHTS

LIGAND AND GSK EXPAND GLOBAL COLLABORATION AND LICENSE AGREEMENT

Ligand Pharmaceuticals | December 22, 2021

news image

Ligand Pharmaceuticals Incorporated announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline. The expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevan...

Read More
news image

INNOVATION PHARMACEUTICALS GRANTS INTELLECTUAL PROPERTY AND COMMERCIALIZATION RIGHTS TO FOX CHASE CHEMICAL DIVERSITY FOR ANTIFUNGAL TECHNOLOGY

Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...

Read More
news image

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

BioSpace: Biotech, | April 01, 2020

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More
news image

BUSINESS INSIGHTS

TREATMENT TO EXPAND GLOBAL LIBRARY OF MEDICINE WITH DERMATOLOGIC DISEASES

Treatment.com International Inc. | January 05, 2022

Treatment.com International Inc. a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these diagnoses will bring another level of accuracy and specificity to the GLM, enhancing soon-to-be-released products such as the Treatment Mobile app, which is set for release this month.
Read More

news image

BUSINESS INSIGHTS

LIGAND AND GSK EXPAND GLOBAL COLLABORATION AND LICENSE AGREEMENT

Ligand Pharmaceuticals | December 22, 2021

Ligand Pharmaceuticals Incorporated announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline. The expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevan...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us